Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 35Lymphoma 10Leukemia, B-Cell 10Leukemia 9Recurrence 8Lymphoma, Non-Hodgkin 7Lymphoma, Large B-Cell, Diffuse 6Lymphoma, Follicular 6Neoplasms 5Bronchiolitis Obliterans Syndrome 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Lymphoma, Mantle-Cell 3Lymphoma, B-Cell 2Hodgkin Disease 2Burkitt Lymphoma 2Waldenstrom Macroglobulinemia 1Thrombocytopenia 1Paraproteinemias 1Oncology Patients Receiving Chemotherapy 1Melanoma 1Lymphoma, B-Cell, Marginal Zone 1Lymphocytosis 1Lymphadenopathy 1Leukemia, Prolymphocytic 1Leukemia, Lymphoid 1Fever 1Fatigue 1Disease 1Agammaglobulinemia 1

Interventions

fludarabine phosphate 29Cyclophosphamide 18Mycophenolic Acid 17Whole-Body Irradiation 16Peripheral Blood Stem Cell Transplantation 16Cyclosporine 13Antilymphocyte Serum 9Tacrolimus 8Cyclosporins 8fludarabine 7Rituximab 7Busulfan 7Filgrastim 6Sirolimus 4Methotrexate 4Cytarabine 4Thiotepa 3Therapeutics 3Melphalan 3Lenalidomide 3Granulocyte Colony-Stimulating Factor 3Etoposide 3Epoetin Alfa 3Darbepoetin alfa 3Cord Blood Stem Cell Transplantation 3Carboplatin 3Allopurinol 3pegfilgrastim 2liposomal amphotericin B 2Radiotherapy 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Leukemia, Prolymphocytic × ofatumumab × Clear all
NCT01515176 2018-03-15

Ofatumumab and Dinaciclib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or B-Cell Prolymphocytic Leukemia

National Cancer Institute (NCI)

Phase 1/2 Completed
36 enrolled 14 charts
LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Prolymphocytic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡